# TG THERAPEUTICS, INC. (TGTX) FY2026 YTD Q2 P&L / Income Statement

- Company: TG THERAPEUTICS, INC. (TGTX)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001437749-26-025955
- Page: https://plicit.ai/financials/tgtx/fy2026-ytd-q2-income-statement
- Chart image: https://plicit.ai/charts/tgtx-fy2026-ytd-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenue**: 445,253,000 US dollars
- **Cost of revenue**: 74,704,000 US dollars
- **Gross profit (calculated)**: 370,549,000 US dollars
- **Operating expenses (calculated)**: 314,080,000 US dollars
- **Operating income**: 56,469,000 US dollars
- **Total other expense**: negative 25,872,000 US dollars
- **Net income before taxes**: 30,597,000 US dollars
- **Income tax expense**: 3,039,000 US dollars
- **Net income**: 27,558,000 US dollars
- **Product**: 437,102,000 US dollars
- **License Revenue**: 8,151,000 US dollars
- **Other research and development**: 130,788,000 US dollars
- **Stock-based compensation**: 12,945,000 US dollars
- **Other selling, general and administrative**: 135,467,000 US dollars
- **Stock-based compensation**: 34,880,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.